AnaptysBio Inc - Company Profile
Powered by 
All the data and insights you need on AnaptysBio Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date AnaptysBio Inc Strategy Report
- Understand AnaptysBio Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
AnaptysBio Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of AnaptysBio Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 08 Apr 2022 | Lorem |
| Boehringer's Phase II spesolimab trial in rare psoriasis faces recruitment delays, at least six months behind schedule, investigators say | 10 Jan 2020 | Reynald Castaneda |
| Regeneron’s Dupixent better meets the moderate-to-severe atopic dermatitis market’s needs compared to AnaptysBio, Dermira’s investigational therapies, experts say | 08 Mar 2019 | Reynald Castaneda |
| AnaptysBio’s Phase II ANB019 for generalised pustular psoriasis and palmopustular psoriasis has most experts desire a 70% response rate | 19 Nov 2018 | Arafa Salam |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer